Connect Biopharma
科望生物
Executive Summary
Connect Biopharma (CNTB) is a Taicang-based biotech with clear BIOSECURE status, making it a viable partner for US pharma deals. The company recently filed its 10-K with SEC disclosures on corporate structure and VIE arrangements, indicating ongoing US market presence and regulatory compliance. Limited public information on pipeline and recent deal activity suggests the need for direct engagement to assess partnership opportunities.
Structure: Connect Biopharma appears to utilize a VIE structure based on 10-K disclosures, typical for Chinese biotechs with US listings. The recent SEC filing indicates active compliance with US regulatory requirements, though specific subsidiary structures and holding company layers require further due diligence review.
Corporate Events
Connect Biopharma 10-K Annual Report
10-K annual report filed with SEC. Contains corporate structure, VIE disclosures, and risk factors.
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, indicating minimal regulatory restrictions for US partnerships
Key Exposures:
- •VIE structure regulatory changes
- •US-China policy shifts
Mitigation: Maintains SEC compliance and clear BIOSECURE status, suggesting proactive regulatory management
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent out-licensing deals identified in available data
Approach: Direct outreach to management team recommended to assess pipeline assets and partnership readiness given limited public information
Red Flags
- ⚠Limited public disclosure of pipeline assets
- ⚠No identified key management personnel
- ⚠Minimal recent business development activity
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 1
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.